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1. Introduction 
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis (Mtb). Robert 
Koch identified Mtb as a causative agent of TB at 1882 (Sakula, 1983). Since then, TB has 
been one of the most important infectious diseases for human being. According to the WHO 
report regarding the global burden of TB in 2009, there were 9.4 million incident cases of TB 
with approximately one third of the world total population being infected (World Health 
Organization, 2010). Especially, coinfection of Mtb and HIV is a serious issue in sub-Sahara 
Africa area. Distribution of multi-drug-resistant TB or extensively drug-resistant TB has 
been another issue in TB.  
The epidemiological studies revealed that only 10 to 30% of people who exposed Mtb are 
infected with Mtb and that 90% or more of the infected people do not develop TB. Only 5% 
shows the symptoms within 1 year and 95% of the infected individuals are considered to 
remain infected latently for the long time. Further, only 5% of individuals who have 
persistently infected Mtb show internal reactivation, i.e., show the overt symptoms the long 
time later (North and Jung, 2004). These facts indicate that immune responses that are 
necessary to contain Mtb are induced in the majority of Mtb-infected individuals. Induction 
of appropriate immune responses against protective Mtb antigens in appropriate stages is 
necessary for preventing TB. In this chapter, we review the aspect of immune responses and 
the vaccine strategies against Mtb. 
2. Protective immunity against Mtb 
2.1 Immune cell effectors against Mtb 
Mtb is a facultative intracellular bacterium that survives in phagosomes of alveolar 
macrophages. In general, effective immune responses against intracellular pathogens are 
based on the cellular arm (T cells), not on the humoral arm (antibodies) of immune 
responses (reviewed in Stenger & Modlin, 1999; Kaufmann, 2003). The followings are 
effective cell subsets that have been considered to be important for protection against Mtb 
infection. 
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2.1.1 CD4
+
 T cells 
Intracellular bacteria in phagosomes including Mtb are processed via major 
histocompatibility complex (MHC) class II-mediated antigen processing pathway and 
antigens of the bacteria are presented to CD4+ helper T cells (reviewed in Kaufmann, 2003; 
Flynn & Chan, 2001; Cooper, 2009). Therefore, CD4+ T cells are considered to be the 
principal effectors against Mtb. Mice that have a deletion in MHC class II or CD4 gene have 
been shown to be succumbed against Mtb challenge infection (Ladel et al., 1995; Caruso et 
al., 1999). CD4+ T cells are divided to mainly two subsets depending on the difference of 
cytokines produced, type 1 helper T cells (Th1) and type 2 helper T cells (Th2). Th1 produces 
interferon (IFN)-, tumor necrosis factor (TNF)-, and/or interleukin (IL)-2, and contribute 
to macrophage activation or granuloma formation through effects of these cytokines. IFN- 
has been reported to be the most critical for the protective immunity through analyses of 
mice or humans which have a deletion in genes encoding IFN- or the receptor (Cooper et 
al., 1993; Flynn et al., 1993; Ottenhoff et al., 1998). Therefore, Th1 has been considered to 
play a pivotal role for protection against Mtb infection. IFN- amounts or the number of 
IFN--producing T cells has been considered to be a relevant marker for induction of a 
protective immunity against Mtb (Ellner et al., 2000; Walzl et al., 2011), although it is not the 
unique marker (Agger & Anderesn, 2001). This cytokine is also able to induce inflammation 
in the lesion, possibly to help aggravating the disease. Th2 produce IL-4, IL-5, and/or IL-10 
and contribute to antibody-mediated immune responses or type 1 allergy development. 
Therefore, Th2 are considered to have inhibitory effects for protective immunity against 
Mtb. 
2.1.2 CD8
+
 T cells 
Theoretically, CD4+ T cells are major effecter cells against phagosome-localized pathogens. 
However, CD8+ T cells also have been shown to play an important role in protective 
immunity against Mtb by analysis of Mtb infection experiments to mice that have deficiency 
in 2-microglobulin gene critical for MHC class I expression (Flynn et al., 1992; Ladel et al., 
1995). Mtb are reported to be cross-presented to CD8+ T cells via MHC class I antigen 
presentation pathway. Kaufmann's group reported that Mtb-infected macrophages induce 
apoptotic process and then cross-presentation via apoptotic vesicles (Winau et al., 2006). The 
process may lead to induction of antigen-specific CD8+ T cells. van Pinxteren and colleagues 
(2000) reported that CD8+ T cells are particularly important in protective immunity at the 
latent phase of TB. 
CD8+ T cells contribute to protective immunity against Mtb in the following mechanisms 
(Smith & Duckrell, 2000; Kaufmann & Flynn, 2005). (1) Secretion of cytokines such as  
IFN- and TNF-. IFN- production is essential for CD8+ T-cell mediation of protective 
immunity against Mtb (Tascon et al., 1998). (2) Lysis of infected host cells through 
perforin and granzyme B secretion. (3) Direct killing of bacteria infected through 
granulysin secretion (Stenger et al., 1997). Stegelmann and colleagues (2005) showed that 
a subset of CD8+ T cells coordinately expresses CC chemokine ligand 5 (CCL5, RANTES), 
perforin and granulysin, attracts Mtb-infected macrophages and kill the intracellular Mtb 
(Stegelmann et al., 2005). 
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2.1.3 Th17 cells 
Th17 is a subtype of CD4+ T cells and produce IL-17. Th17 promote migration of Th1, 
neutrophils, and monocytes to TB lesion in the presence of chemokines and contribute to 
protective immunity against Mtb (Khader et al., 2007).  
2.1.4 CD1-restricted T cells 
A subset of T cells is antigen-presented through CD1 molecules, not through conventional 
MHC class I (Ia) or II molecules. Genes encoding CD1 molecules are mapped outside of 
MHC and are less polymorphic than conventional MHC genes. CD1-restricted T cells have 
been reported to recognize glycolipids in mycobacterial cell wall such as mycolic acid 
(Beckman et al., 1994). 
2.1.5.  T cells 
Most CD4+ and CD8+ T cells express T-cell receptors of  and  protein chains. A minor 
subset of T cells expresses T-cell receptor of  and  protein chains ( T cells).  T cells tend 
to distribute in epithelial tissues and contribute to early protection against pathogens 
invading through epithelium. The phosphoantigen-specific  T cells (V2V2+) displayed 
major expansion during BCG infection and a clear memory-type response after BCG 
reinfection in a macaque model (Shen et al., 2002).. 
2.1.6 NK cells 
NK cells have been associated with early resistance against Mtb (Junqueira-Kipnis et al., 
2003). NK cells increased in the lung after aerosol infection of Mtb and produce IFN- and 
perforin. But in vivo NK cell depletion experiment had no influence on bacterial load within 
the lungs in mouse system, suggesting that NK cells do not play essential roles in early stage 
of Mtb infection. 
2.1.7 Regulatory T cells 
Regulatory T cells (Treg) are composed of a subset of T cells that express Foxp3 transcription 
factor and inhibit effector T-cell responses by both cell-to-cell direct contact and secretion of 
inhibitory cytokines such as IL-10 or transforming growth factor (TGF)-. They also 
constitutively express CD25 molecule,  chain protein of the high affinity IL-2 receptor. So, 
this T-cell subset can be deleted in vivo with injection of anti-CD25 monoclonal antibody 
and the depletion experiments confirmed that it has been shown to be critical for prevention 
of autoimmunity and graft rejection. Treg have been reported to be induced in Mtb-infected 
mice and humans and this cell subset is considered to be important for the persistence of 
Mtb infection (Kursar et al., 2007). 
2.1.8 Antibodies 
In general, humoral immunity does not contribute to induction of the protective immunity 
against Mtb. However, antibodies specific for heparin-binding haemagglutinin (HBHA) and 
arabinomannan are reported to contribute to reduce the bacterial load in lung (Teitelbaum et 
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al., 1998; Pethe et al., 2001). Antibodies specific for antigens presented on the surface of Mtb 
may have some effect to prevent invading Mtb into the host cells. 
2.2 Protective antigens of Mtb 
The analysis of genome of Mtb H37Rv strain reveals that 3,985 open reading frames exist 
in the genome (Cole et al., 1998). Since the report, DNA vaccines are possible to be 
constructed through the genome information. Information of mycobacterial genes and 
proteins is available from several comprehensive databases (e.g., The Pasteur Institute 
TubercuList [http://genolist.pasteur.fr/tuberculist/], The Institute for Genomic Research 
(TIGR) Comprehensive Microbial Resource (CMR) [http://cmr.tigr.org/tigr-
scripts/CMR/CmrHomePage.cgi]). The most important issue in developing effective TB 
vaccines is to clarify which genes or gene products are important for the protective 
immunity against Mtb. The fact that viable Mtb, but not killed Mtb, can induce the 
protective immunity (Orme, 1988) leads to the speculation that mainly secretory proteins 
would be the protective antigens. In fact, the majority of the target antigens of the cellular 
arm of immunity has been reported to be secretory or cell-membrane proteins (Andersen, 
1994). Representative protective antigens of Mtb have been clarified by analyses of T-cell 
responses against protein fractions separated with the electrophoresis analyses (Belisle et 
al., 2005). The followings are the representative protective antigens of Mtb reported. 
2.2.1 Antigen 85 complex proteins 
Antigen 85 (Ag85) complex proteins are mycobacterial major secreted proteins of 30 to 32 
kDa. The proteins have mycolyl transferase function that is necessary for synthesis of lipid 
components of mycobacterial cell wall and fibronectin-binding function (Wiker & Harboe, 
1992; Belisle et al., 1997). Ag85 complex proteins are composed of Ag85A (p32A), Ag85B 
(p30, MPT59,  antigen), and Ag85C protein. These proteins are well conserved in 
Mycobacterium genus. MPT51 protein has some homology to these proteins (Nagai et al., 
1991; Ohara et al., 1995) and has been shown to be a protective antigen (Miki et al., 2004).  
2.2.2 Low-molecular-mass secretory proteins 
Low-molecular-mass proteins (less than 20 kDa) in Mtb culture fluid proteins (CFPs) have 
been reported to be major antigens that evoke T-cell responses (Boesen et al., 1995; Demissie 
et al., 1999). Among a variety of low-molecular-mass secreted proteins, early secreted 
antigenic target 6-kDa protein (ESAT6) and culture fluid protein 10 (CFP10) have been well 
studied (Berthet et al., 1998). Recently, ESAT6 and CFP10 proteins are widely used in whole 
blood IFN- release assays for TB diagnosis (Andersen et al., 2000) (QuantiFERON® TB 
Gold; Cellestis, Ltd., Carnegie, Victoria, Australia). 
2.2.3 Heat shock proteins 
A variety of heat shock proteins have been shown to be targets for antibodies and T cells in 
murine and human systems. Among them, heat shock protein 65 (Hsp65) is a major stress 
protein Mtb produces in macrophage cells. Mtb Hsp65 protein has more than 50% 
homology with Escherichia coli GroEL or human Hsp60 protein (Lee & Horwitz, 1995). Heat 
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shock proteins have been shown to be expressed in Mtb in macrophages and induce 
protective immune responses. 
2.2.4 Dormant phase proteins 
Aforementioned proteins are expressed mainly in acute phage of TB. A different set of genes 
are expressed in late infection phase or chronic (dormant) phase of TB. DosR regulon is a 
unit of genes composed of 48 genes, the expression of which is regulated by DosR (Rv3133c). 
DosR regulon proteins are the major proteins expressed in chronic (dormant) phase of TB 
(Karalousis et al., 2004). HspX protein (Rv2031c) is one of the immunodominant antigens 
belong to DosR regulon proteins. It plays an important role in slowing the growth of Mtb as 
hspX gene-deleted Mtb mutants showed increased growth both in mice and in macrophages 
(Hu et al., 2006). T-cell responses specific for HspX were found in latent Mtb infection 
(Demissie et al., 2006). In addition, mycobacterial DNA-binding protein-1 (MDP1) has been 
shown to be expressed in the late phase of TB and induce humoral and cellular immune 
responses (Matsumoto et al., 2005; Suzuki et al., 2010). Analysis of dormant phase proteins is 
critical for development of therapeutic TB vaccines against persistent Mtb infection. 
2.3 T-cell epitopes of Mtb proteins 
T-cell epitopes are the peptides in antigenic proteins that bind to MHC molecules on 
antigen-presenting cells. In other words, T-cell epitopes are the peptides that stimulate T 
cells through the MHC-T-cell receptor interaction.  
 
Fig. 1. Shematic diagram for identification of T-cell with DNa immunization 
Identification of T-cell epitopes in Mtb antigens is indispensable for accurate analysis of T-
cell responses against Mtb antigens with specific MHC tetramers or intracellular cytokine 
staining. We realized that DNA immunization with gene gun bombardment is an excellent 
method for identification of Mtb T-cell epitopes as it is highly reproducible and efficiently 
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Table 1. Human T-cell epitopes of Mtb antigens (examples) 
induces T-cell responses (Yoshida et al., 2000). Therefore, we have used gene gun DNA 
immunization method for identification of CD8+ and CD4+ T-cell epitopes of Mtb antigens 
(Fig. 1). After immunization with plasmid DNA encoding Mtb antigens, immune spleen cells 
were examined for their IFN- responses to overlapping peptides covering full-length Mtb 
antigens by measuring IFN- levels by enzyme-linked immunosorbent assay (ELISA) or by 
counting the numbers of IFN--secreting cells by enzyme-linked immunospot assay 
(ELISPOT). We combined these methods with computer algorithms to predict T-cell epitopes. 
T-cell epitope prediction algorithm programs we used are as follows. They are able to access 
through their websites. (1) SYFPEITHI Epitope program (http://www.syfpeithi.de/) 
(Rammensee et al., 1999), (2) the National Institutes of Health Bioinformatics and Molecular 
Analysis Section (BIMAS) HLA Peptide Binding Predictions (http://bimas.dcrt.nih.gov/cgi-
bin/molbio/ken_parker_comboform) (Parker et al., 1994), RANKPEP MHC binding peptide 
prediction algorithm (http://immunax.dfci.harvard.edu/Tools/rankpep.html) (Reche et al., 
2004), and (4) ProPred HLA-DR binding peptide prediction algorithm 
(http://www.imtech.res.in/raghava/propred/) (Singh & Raghava, 2001). These programs are 
helpful for narrowing down the amino acid regions of T-cell epitopes. However, the 
algorithms are still not perfect for exact identification of bona fide T-cell epitopes. A peptide 
that shows the highest score in these algorithms is not necessarily the best T-cell epitope. 
Experimental validation is definitely necessary to determine actual T-cell epitopes. A variety of 
www.intechopen.com
 
Immune Responses Against Mycobacterium tuberculosis and the Vaccine Strategies 
 
397 
T cell epitopes of Mtb antigens have been reported. A comprehensive analysis of T-cell epitope 
data regarding Mycobacterium genus in the immune epitope database (IEDB; 
http://immuneepitope.org) was performed (Blythe et al., 2007). Huygen and colleagues have 
reported identification of murine T-cell epitopes of Ag 85 family proteins (Ag85A, Ag85B, and 
Ag85C) (Denis et al., 1998, D'Souza, et al., 2003) using intramuscular DNA immunization. We 
have used gene gun DNA immunization method for identification of murine CD8+ and CD4+ 
T-cell epitopes of Mtb antigens including MPT51 (Suzuki et al., 2004), MDP1 (Suzuki et al., 
2010), and low-molecular-mass secretory antigens (CFP11, CFP17, and TB18.5) (Eweda et al., 
2010). 
In addition to murine T-cell epitopes, human T-cell epitopes have been reported (some 
examples are shown in Table 1). HLA-A02 is the most frequent HLA molecule in Caucasians 
and HLA-A*0201 represents the most frequent allele. HLA-A*0201-restricted CD8+ T-cell 
epitopes have been identified in a variety of antigens including those derived from cancers, 
viruses, bacteria, and protozoan. Mtb-derived HLA-A*0201-restricted CD8+ T-cell epitopes 
have been reported, including epitopes in Ag85A (Smith et al., 2000), Ag85B (Geluk et al., 
2000), ESAT6 (Lalvani et al., 1998), and Hsp65 (Charo et al., 2001). 
 
 
Table 2. HLA-A*0201-restricted T-cells epitopes od Mtb antigens (examples) 
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Most HLA-A*0201-restricted T-cell epitopes were nonamer peptides (Falk et al., 1991, 
Parker, 1994), but some epitopes were decamer peptides. We reported an immunodominant 
HLA-A*0201-restricted T-cell epitope in MPT51 antigen (Aoshi et al., 2008; Tables 1, 2). Main 
anchor amino acid positions are, position 2 (Leu) and position 9 (Val), which were 
conserved in MPT51 p53-62 (TLAGKGISVV) (Table 2). MPT51 p53-62 decamer peptide was 
capable of binding to HLA-A*0201 and of stimulating CD8+ T cells of HLA-A*0201-
transgenic mice, but MPT51 p53-61 nonamer was not. The conformational and electrostatic 
differences between the nonamer and the decamer would affect their binding affinity to 
HLA-A*0201 molecule and following T-cell responses. Ruppert and colleagues (1993) 
studied in detail the role of different amino acid residues on each position of nonamer or 
decamer peptides for binding to HLA-A*0201 molecule. They suggested that nonamer or 
decamer peptide has different preference of amino acid residues for binding to HLA-A*0201 
molecule. They showed that, for example, Tyr, Phe, Trp residues at positions 1, 3, and 5 in 
nonamer peptides, Gly residues at positions 4 and 6 in decamer peptides are preferable for 
binding to HLA-A*0201. According to their speculation, MPT51 p53-62 peptide seems to 
have better A*0201 binding features than MPT51 p53-61 peptide (Gly residues at positions 4 
and 6 in MPT51 p53-62 peptide are suggested to be associated with good A*0201 binding). 
Interestingly, MPT51 p21-29 peptide (FLAGGPHAV) was not immunogenic in terms of IFN-
 production and cytolytic ability although the peptide showed high affinity to HLA-A*0201 
as predicted by MHC binding algorithms (Aoshi et al., 2008). Previous reports showed a 
strong association between immunodominance and HLA binding affinity (Geluk et al., 
1998). But, binding of peptides to the restricted MHC molecules is a prerequisite for T-cell 
epitopes, but all the peptides which show high affinity binding for MHC molecules are not 
necessarily immunodominant epitopes. 
3. Vaccine strategies against Mtb 
3.1 Recombinant BCG vaccines 
Mycobacterium bovis bacillus Calmette-Guérin (BCG) is the only approved attenuated live 
vaccine to date against TB. Original BCG strain was reported approximately ninety years 
ago (1921) by Calmette and Guérin (Bloom & Fine, 1994). Despite the fact that BCG is among 
the most widely used vaccine throughout the world since then, TB still poses a serious 
global health threat. Whereas BCG is believed to protect newborns and young children 
against early manifestations of TB (Rodgrigues et al., 1993), its efficacy against pulmonary 
TB in adults is still a subject of debate (Bloom & Fine, 1994; Andersen & Doherty, 2005) and 
was reported to wane with time since vaccination (Sterne et al., 1998). Variable levels of the 
protective efficacy ranging from 0 to 80% have been reported in different studies (Fine, 
1995). Moreover, the viable nature of BCG makes it partly unsafe in case of 
immunocompromised people such as HIV-infected individuals. This highlights the need to 
develop more effective, safe and reliable vaccines against TB (Kaufmann, 2010). 
To improve the immunoreactivity of conventional BCG vaccines, a variety of recombinant 
BCG (rBCG) vaccines have been tried and evaluated for the protective efficacy (Stover et al., 
1991). One of the problems of conventional BCG vaccines in induction of protective immune 
responses is that BCG is not effective for induction of CD8+ T-cell responses compared with 
Mtb. BCG is less effective in MHC class I-mediated antigen presentation, which is 
prerequisite for CD8+ T-cell induction (Mazzaccaro et al., 1996). To improve CD8+ T-cell 
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responses of BCG, Kaufmann and colleagues reported recombinant BCG (rBCG) introduced 
with listeriolysin O (LLO) gene derived from Listeria monocytogenes (Hess et al., 1998). L. 
monocytogenes escapes from the phagosomes into the cytoplasm shortly after infection into 
host macrophage cells. LLO, a thiol-activated cytolysin, has membrane-disrupting capability 
and plays a pivotal role in this process. The rBCG expressing LLO was reported to improve 
MHC class I-mediated antigen presentation of co-phagocytosed ovalbumin, suggesting that 
LLO endows BCG with an improved capacity to stimulate CD8+ T cells. Further, the same 
group constructed urease C gene (ureC)-disrupted rBCG expressing LLO (Grode et al., 2005). 
Mycobacterial ureC increases pH value in the phagosome. The ureC deficiency induces low 
pH value in the phagosome, helping the LLO enzyme activity (to disrupt phagosome 
membranes), which leads enhancement of MHC class I-mediated CD8+ T-cell responses. 
Another promising rBCG is BCG overexpressing Ag85B protein (Horwitz et al., 2000). 
Ag85B is a major mycobacterial secreted protein and has been shown to be a protective 
antigen. Even though BCG does have endogenous Ag85B, overexpression of Ag85B in BCG 
was further enhanced the protective ability. In addition to these rBCG, attenuated auxotroph 
strains of Mtb have been examined (Guleria et al., 1996; Sambandamurthy et al., 2006; 
Larsen et al., 2009). 
3.2 DNA Vaccination against TB 
Many reports on DNA vaccination against Mtb have been published since 1996 (Huygen et 
al., 1996, Tascon et al., 1996). So far, a variety of Mtb antigen genes have been used for DNA 
vaccines, which include Hsp 65, Hsp 70, Ag85A, Ag85B, and ESAT6 (reviewed in Huygen, 
2003 for early studies). DNA immunization with genes encoding dormancy regulon-
encoded proteins has also been examined (Roupie et al., 2007). DNA immunization with 
naked DNA has been shown to efficiently induce cellular as well as humoral immune 
responses. DNA vaccines in most of these reports use needle injection through 
intramuscular or intradermal routes although some studies used gene gun (Sugawara et al., 
2003). The DNA immunization with needle injection tends to raise predominant Th1 
responses which are indispensable for induction of the protective immunity. On the other 
hand, gene gun DNA immunization is apt to produce “mixed type” (Th1 and Th2; 
producing IFN- and IL-4) T-cell responses which is not necessarily adequate for induction 
of the protective immunity (Tanghe et al., 2000). The difference is considered to be mainly 
due to the difference in the amount of antigen produced from the plasmids (high amounts 
in needle injection and low amounts in gene gun bombardment). Therefore, DNA 
vaccination with gene gun will need additional factors such as adjuvants for eliciting 
protective immunity against Mtb (D’Souza et al., 2002; Tollefsen et al., 2002; Li et al., 2006; 
Zhang et al., 2007).  
Naked DNA vaccines have been evaluated as therapeutic TB vaccines as well as 
prophylactic TB vaccines. Lowrie and colleagues (1999) showed that intramuscular injection 
of mice with Hsp65 and MPT70 DNA vaccines reduced Mtb numbers in spleens and lungs 
after Mtb challenge by 1 to two log10 order compared with untreated mice. Further, they 
showed that three intramuscular injection of Hsp65 DNA vaccine eliminated residual Mtb 
after chemotherapy (isoniazid and pyrazinamid treatment) and immunosupprssive 
corticosteroid treatment. However, Orme's group reported that Ag85A DNA vaccine that 
was shown to induce protective immunity in mice when the vaccine was used as a 
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prophylactic vaccine, could not give any therapeutic effect on the course of the infection in 
the lungs in mice earlier infected by Mtb aerosol (Turner et al., 2000). Moreover, they 
reported that vaccination with DNA encoding hsp60 of Mycobacterium leprae induced 
cellular necrosis throughout the lung granulomas when the DNA was given in a mouse 
immunotherapeutic model (Taylor et al., 2003). Repique and colleagues (2002) also reported 
that vaccination with a DNA vaccine cocktail containing ten Mtb antigen genes which had 
showed significant protective responses in mice could not prevent reactivation of disease in 
a murine latent TB model. These reports indicate that therapeutic TB vaccines still have 
room for further studies in terms of safety.  
3.3 Improvement in immunization regimen: prime-boost immunization 
Evaluation of vaccination has indicated that the repeated injection of the same vaccine has a 
limitation in terms of its overall immunological effects. Especially, DNA immunization has 
been reported to induce considerably strong immunological responses in the rodents, but 
not in the primates including human (Li et al., 1993). Instead of the repeated injection of the 
same vaccine, the heterologous prime-boost regimen including DNA vaccination, which is 
primed with naked DNA vaccination and boosted with recombinant viral vectors such as 
vaccinia virus and adenovirus, has been shown to evoke superior levels of immunity to 
DNA vaccine or recombinant virus alone (Ramshaw & Ramsay, 2000). The relatively low-
level but persistent expression of immunogenic proteins in vivo by naked DNA vaccines has 
been suggested to be important for priming immunological responses and inducing 
enhanced cellular immunity (Ramshaw & Ramsay, 2000). 
A variety of prime-boost regimens have been examined for Mtb infection (McShane & Hill, 
2005). Many investigators examined the regimens in which priming with DNA vaccines and 
boosting with other immunization strategies. Feng and colleagues (2001) showed that 
priming with Ag85B DNA vaccine and boosting with BCG vaccine strengthened protective 
immunity against Mtb induced by BCG vaccine alone in mice. Skinner and colleagues (2003) 
also reported that priming with ESAT6 andAg85A DNA vaccines and boosting with BCG 
vaccine enhanced specific IFN- production from immune splenocytes compared with that 
by the DNA vaccine or BCG vaccine alone in mice. Ferraz and colleagues (2004) used DNA 
vaccines encoding mycobacterial Hsp70, Hsp65, and Apa antigens as priming vaccine and 
showed that the DNA vaccines enhanced BCG boosting effects. Romano and colleagues 
(2006) showed that immunization of BALB/c mice with Ag85A DNA vaccine first and 
boosting with BCG vaccine induced stronger protective immunity against Mtb challenge 
than that by Ag85A DNA vaccine alone. These results demonstrated that DNA vaccine 
priming and BCG vaccine boosting enhanced immune responses induced by BCG vaccine 
alone. 
The regimens in which BCG vaccine was used as a priming vaccine also have been tried. As 
the BCG vaccine has been injected to people all over the world, this regimen seems to be 
reasonable. Derrick and colleagues (2004) showed that a polyvalent DNA vaccine encoding 
an ESAT6-Ag85B fusion protein protects mice against a primary Mtb infection and boosts 
BCG-induced protective immunity. Priming with BCG vaccine and intranasal boosting with 
MVA85A in mice enhanced Ag85A-specific CD4+ and CD8+ T-cell responses and 
strengthened protective immunity against aerosol Mtb challenge infection in mice 
(Goonetilleke et al., 2003). This regimen was reported in humans. McShane and colleagues 
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(2004) reported that in volunteers who had been vaccinated 0.5 to 38 years previously with 
BCG, vaccination with MVA85A induced substantially higher levels of antigen-specific IFN-
-secreting T cells and that at 24 weeks after vaccination, these levels were 5 to 30 times 
greater than in vaccinees administered a single BCG vaccination.  
3.4 Ongoing tuberculosis vaccine projects 
A variety of TB vaccines have been evaluated (reviewed in Hoft, 2008; Kaufmann, 2010a, 
2010b).  WHO have showed a list of TB vaccine candidates (TB vaccine pipeline: 
http://www.stoptb.org/retooling/). These TB vaccine strategies are based on the prime-
boost regimens and the vaccine candidates are categorized into three vaccine groups, 
namely, (1) priming vaccines, (2) boosting vaccines, and (3) therapeutic vaccines after Mtb 
infection. Some of vaccine candidates that have been ongoing are shown in Table 3. 
 
Table 3. TB vaccine candidates (According to WHO TB Vaccine Pipeline) 
BCG vaccines and rBCG vaccines are considered to be priming vaccines. For priming 
vaccines, BCG overexpressing Ag85B (rBCG30) and ureC-deleting BCG expressing 
lysteriolysin O (ureC hly+ BCG) have been evaluated. For booster vaccines, Ag85A 
recombinant vaccinia virus (MVA85A), Ag85B-ESAT6 fusion protein with adjuvant (SSI 
Hybrid I), and Ag85B-TB10.4 fusion protein with adjuvant (SSI HyVac4/AERAS-404) have 
been examined. MVA85A and Hsp65 DNA vaccine are candidate TB vaccine are candidate 
therapeutic TB vaccines. Human studies using the prime-boost regimens by these TB 
vaccine candidates have been publishing. Tchilian and colleagues (2009) reported that 
priming with ureC hly+ BCG and boosting with MVA85A induced protective immunity 
against Mtb infection in mice. The protective effects were much higher in ureC hly+ BCG 
vaccination than that in parental BCG vaccination. MVA85A boost immunization enhanced 
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Ag85A-specific T-cell responses, but did not affect bacterial numbers in the lung after Mtb 
aerosol infection. Scriba and colleagues (2010) reported that vaccination with MVA85A in 
healthy adolescents and children from a TB endemic region, who received BCG at birth, is 
safe and induces polyfunctional CD4+ T cells co-expressing IFN-, TNF-, and IL-2. Further, 
Abel and colleagues (2010) reported that vaccination with AERAS-402 (Adenovirus type 35 
expressing a fusion protein created from the sequences of Ag85A, Ag85B, and TB10.4) is safe 
and immunogenic in healthy South African BCG-vaccinated adults. 
4. Conclusion 
Mtb, a causative agent of TB, is a unique facultative intracellular bacterium. The cellular 
immunity is essential for protection against Mtb. The main effectors are type 1 CD4+ T cells 
and CD8+ T cells. IFN- produced from them has been considered to be important as 
biomarker of TB. Induction of appropriate immune responses against protective Mtb 
antigens in appropriate stages is necessary for preventing TB. Identification of protective 
Mtb antigens and the T-cell epitopes are critical for clarification of kinetics of TB and 
development of effective TB vaccines. A variety of TB vaccine strategies have been 
examined including rBCG and DNA vaccines. Prime-boost strategies with combination of 
different TB vaccines are promising for prophylactic TB vaccines. Therapeutic TB vaccines 
for latent TB have also been examined. 
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